MorphoSys (MOR) Given a €97.00 Price Target by JPMorgan Chase & Co. Analysts
Several other brokerages also recently commented on MOR. Berenberg Bank set a €85.00 ($101.19) price objective on shares of MorphoSys and gave the company a buy rating in a research report on Thursday, December 7th. Commerzbank set a €76.00 ($90.48) price objective on shares of MorphoSys and gave the company a buy rating in a research report on Tuesday, November 7th. Goldman Sachs Group set a €55.00 ($65.48) price objective on shares of MorphoSys and gave the company a neutral rating in a research report on Tuesday, September 19th. Deutsche Bank set a €90.00 ($107.14) price target on shares of MorphoSys and gave the company a buy rating in a report on Monday, October 30th. Finally, Independent Research set a €77.00 ($91.67) price target on shares of MorphoSys and gave the company a buy rating in a report on Thursday, September 7th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of Buy and an average price target of €83.75 ($99.70).
MorphoSys (MOR) traded up €1.45 ($1.73) on Thursday, reaching €80.85 ($96.25). 93,899 shares of the company’s stock traded hands, compared to its average volume of 132,632. The company has a market capitalization of $2,340.00 and a P/E ratio of -27.41. MorphoSys has a fifty-two week low of €46.50 ($55.36) and a fifty-two week high of €83.83 ($99.80).
ILLEGAL ACTIVITY WARNING: “MorphoSys (MOR) Given a €97.00 Price Target by JPMorgan Chase & Co. Analysts” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/morphosys-mor-given-a-97-00-price-target-by-jpmorgan-chase-co-analysts/1795899.html.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with Analyst Ratings Network's FREE daily email newsletter.